Table 1.
Incidence of lung adenocarcinoma in cohorts of wild-type and Dok mutant mice
| 11–15 months |
> 15 months |
Overall (11–25 months) |
|||||
|---|---|---|---|---|---|---|---|
| Genotype | n with cancer/ total n |
% | n with cancer/ total n |
% | n with cancer/ total n |
% |
P value compared to WT& |
| WT | 0/13 | 0% | 3/30 | 10% | 3/43 | 7% | - |
| Dok1 KO | 1/8 | 13% | 14/32 | 44% | 15/40 | 38% | 0.001 |
| Dok2 KO | 1/9 | 11% | 12/46 | 26% | 13/55 | 24% | 0.0303 |
| Dok3 KO | 1/6 | 17% | 16/37 | 43% | 17/43 | 40% | 0.0006 |
| Dok1/Dok2 DKO | 3/14 | 21% | 8/20 | 40% | 11/34 | 32% | 0.0064 |
| Dok1/Dok3 DKO | 6/15 | 40% | 14/24 | 58% | 20/39 | 51% | <0.0001 |
| Dok2/Dok3 DKO | 4/11 | 36% | 15/26 | 58% | 19/37 | 51% | <0.0001 |
| TKO | 4/8 | 50% | 17/25 | 68% | 21/33 | 64% | <0.0001 |
&
For each Dok mutant genotype, the overall incidence of lung adenocarcinoma at 11–25 months of age was compared to that of the wild-type cohort using a Fisher's Exact test with a P value less than 0.05 considered significant.